BMEA
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc. (BMEA) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | D (1.3) | D- (0.8) | D (1.3) | C+ (2.6) | D+ (1.7) |
| 2026-11-10 | C+ (2.5) | D+ (1.8) | C (2.5) | C- (2.1) | C+ (2.6) | C (2.3) |
| 2026-11-03 | C+ (2.5) | D+ (1.7) | C+ (2.5) | C- (1.9) | C+ (2.7) | C (2.3) |
| 2026-10-27 | C+ (2.5) | D+ (1.8) | C+ (2.5) | D+ (1.7) | C+ (2.6) | C (2.2) |
| 2026-10-20 | C+ (2.5) | D+ (1.8) | C+ (2.5) | C- (2.1) | C+ (2.6) | C (2.3) |